Revisiting the differentiation paradigm in acute promyelocytic leukemia
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
As the result of intense clinical and basic research, acute promyelocytic leukemia (APL) has progressively evolved from a deadly to a curable disease. Historically, efforts aimed at understanding the molecular bases for therapy response have repeatedly illuminated APL pathogenesis. The classic model attributes this therapeutic success to the transcriptional reactivation elicited by retinoic acid and the resulting overcoming of the differentiation block characteristic of APL blasts. However, in clinical practice, retinoic acid by itself only rarely yields prolonged remissions, even though it induces massive differentiation. In contrast, as a single agent, arsenic trioxide neither directly activates transcription nor triggers terminal differentiation ex vivo, but cures many patients. Here we review the evidence from recent ex vivo and in vivo studies that allow a reassessment of the role of differentiation in APL cure. We discuss alternative models in which PML-RARA degradation and the subsequent loss of APL cell self-renewal play central roles. Rather than therapy aimed at inducing differentiation, targeting cancer cell self-renewal may represent a more effective goal, achievable by a broader range of therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia
Tallman, M. S., Andersen, J. W., Schiffer, C. A., Appelbaum, F. R., Feusner, J. H., Ogden, A., Shepherd, L., Willman, C., Bloomfield, C. D., Rowe, J. M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371501 · Cited by 1,073
Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML
Zhang, X.-W., Yan, X.-J., Zhou, Z.-R., Yang, F.-F., Wu, Z.-Y., Sun, H.-B., Liang, W.-X., Song, A.-X., Lallemand-Breitenbach, V., Jeanne, M., et al. (2010) · Science · doi:10.1126/science.1183424 · Cited by 785
Muindi, J., Frankel, Sr., Miller, W. J., Jakubowski, A., Scheinberg, D., Young, C., Dmitrovsky, E., & Warrell, R. J. (1992) · Blood · doi:10.1182/blood.v79.2.299.299 · Cited by 314
Guibal, F. C., Alberich-Jorda, M., Hirai, H., Ebralidze, A., Levantini, E., Di Ruscio, A., Zhang, P., Santana-Lemos, B. A., Neuberg, D., Wagers, A. J., et al. (2009) · Blood · doi:10.1182/blood-2008-10-182071 · Cited by 126
Cited by
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Differentiation therapy revisited
de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462
Leiva, M., Moretti, S., Soilihi, H., Pallavicini, I., Peres, L., Mercurio, C., Dal Zuffo, R., Minucci, S., & de Thé, H. (2012) · Leukemia · doi:10.1038/leu.2012.39 · Cited by 58
Coltella, N., Valsecchi, R., Ponente, M., Ponzoni, M., & Bernardi, R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3022 · Cited by 49
“Acute promyelocytic leukemia (APL) represents a well-defined subtype of acute myelogenous leukemia (AML) characterized in about 95% of cases by the oncogenic fusion protein PML-RARa resulting from the chromosomal translocation t(15;17) (1).”
BackgroundInfluentialRetinoid Differentiation Therapy for Common Types of Acute Myeloid Leukemia
Brown, G., & Hughes, P. (2012) · Leukemia Research and Treatment · doi:10.1155/2012/939021 · Cited by 39
Metadata
- Authors
- Ablain, J., & de The, H.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-06-02
- Volume
- 117
- Issue
- 22
- Pages
- 5795-5802
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2004294093
- Cited by
- 124
- References
- 4
- FWCI
- 6.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Revisiting the differentiation paradigm in acute promyelocytic leukemia. https://app.cochat.ai/papers/10.1182/blood-2011-02-329367
- The paper
- Ablain, J., & de The, H. (2011). Revisiting the differentiation paradigm in acute promyelocytic leukemia. Blood. https://doi.org/10.1182/blood-2011-02-329367
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.